Last reviewed · How we verify
LCS12
LCS12 is a small molecule that inhibits the PCSK9 enzyme.
LCS12 is a small molecule that inhibits the PCSK9 enzyme. Used for Hypercholesterolemia.
At a glance
| Generic name | LCS12 |
|---|---|
| Sponsor | Bayer |
| Drug class | PCSK9 inhibitor |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PCSK9, LCS12 increases the levels of low-density lipoprotein (LDL) receptors on the liver surface, leading to reduced levels of LDL cholesterol in the blood.
Approved indications
- Hypercholesterolemia
Common side effects
- Musculoskeletal pain
Key clinical trials
- European Active Surveillance Study of LCS12
- LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study (PHASE3)
- Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study (PHASE3)
- LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study (PHASE3)
- LCS12 Adolescent Study (PHASE3)
- Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LCS12 CI brief — competitive landscape report
- LCS12 updates RSS · CI watch RSS
- Bayer portfolio CI